Li Wang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Top Venues

British journal of pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Huanyu Ding, Minchun Jiang, Andrew Man Lok Chan, Yin Xia, Ronald Ching-Wan Ma, Xiaoqiang Yao, Li Wang, Yu Huang
Targeting the tyrosine kinase Src in endothelium attenuates inflammation and atherogenesis induced by disturbed flow. British journal of pharmacology (2024)
Huanyu Ding, Minchun Jiang, Chi Wai Lau, JianFang Luo, Andrew Man Lok Chan, Li Wang, Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of Src-YAP signaling axis. British journal of pharmacology (2022)
Huanyu Ding, Minchun Jiang, Chi Wai Lau, JianFang Luo, Andrew Man Lok Chan, Li Wang, Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis. British journal of pharmacology (2022)
Huanyu Ding, Minchun Jiang, Chi Wai Lau, JianFang Luo, Andrew Man Lok Chan, Li Wang, Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis. British journal of pharmacology 180 (8) (2022)
Huanyu Ding, Minchun Jiang, Chi Wai Lau, JianFang Luo, Andrew Man Lok Chan, Li Wang, Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis. British journal of pharmacology 180 (8) (2022)
Huanyu Ding, Minchun Jiang, Chi Wai Lau, JianFang Luo, Andrew Man Lok Chan, Li Wang, Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis. British journal of pharmacology 180 (8) (2022)